RSV vaccines protect against the respiratory syncytial virus that affects the respiratory tract. The signs of illness after an infection are in most cases similar to those of a cold.
| Name | Description | Marketing Authorisation Holder | Kind of Vaccine | License Number | License Date | Further Information |
|---|---|---|---|---|---|---|
Abrysvo |
Respiratorischer Synzytial-Virus-Impfstoff (rekombinant) Verwendung ab einem Lebensalter von 60 Jahren / Use from 60 years of age onwards Verwendung bei schwangeren Personen zum Schutz des Säuglings ab der Geburt bis zu einem Alter von 6 Monaten / Use in pregnant persons to protect the infant from birth to 6 months of age |
Pfizer Europe MA EEIG, Belgien |
Bivalent | EU/1/23/1752 | 23.08.2023 | |
Arexvy |
Respiratorischer Synzytial-Virus-Impfstoff (rekombinant, adjuvantiert) Verwendung ab einem Lebensalter von 60 Jahren / Use from 60 years of age onwards |
GlaxoSmithKline Biologicals S.A. |
Mono | EU/1/23/1740 | 06.06.2023 | |
mResvia |
Respiratorisches-Synzytial-Virus-mRNA-Impfstoff Verwendung ab einem Lebensalter von 60 Jahren / Use from 60 years of age onwards |
Moderna Biotech Spain S.L. |
Mono | EU/1/24/1849 | 22.08.2024 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 25.04.2025
